X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA FRESENIUS KABI ONCO. AJANTA PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 25.0 22.1 113.1% View Chart
P/BV x 10.3 3.1 331.7% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 AJANTA PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
FRESENIUS KABI ONCO.
Mar-13
AJANTA PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,720176 977.3%   
Low Rs1,10379 1,405.1%   
Sales per share (Unadj.) Rs194.637.7 516.4%  
Earnings per share (Unadj.) Rs45.25.1 887.8%  
Cash flow per share (Unadj.) Rs50.36.7 748.1%  
Dividends per share (Unadj.) Rs8.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs132.042.5 310.3%  
Shares outstanding (eoy) m88.77158.23 56.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.33.4 214.8%   
Avg P/E ratio x31.225.0 124.9%  
P/CF ratio (eoy) x28.118.9 148.3%  
Price / Book Value ratio x10.73.0 357.4%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m125,29920,135 622.3%   
No. of employees `000NA1.2 0.0%   
Total wages/salary Rs m2,570703 365.5%   
Avg. sales/employee Rs ThNM5,176.2-  
Avg. wages/employee Rs ThNM610.4-  
Avg. net profit/employee Rs ThNM699.6-  
INCOME DATA
Net Sales Rs m17,2755,963 289.7%  
Other income Rs m16618 923.9%   
Total revenues Rs m17,4425,981 291.6%   
Gross profit Rs m5,8071,430 406.1%  
Depreciation Rs m451258 174.7%   
Interest Rs m49-26 -188.1%   
Profit before tax Rs m5,4741,216 450.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,460342 426.6%   
Profit after tax Rs m4,014806 498.1%  
Gross profit margin %33.624.0 140.2%  
Effective tax rate %26.728.1 94.8%   
Net profit margin %23.213.5 171.9%  
BALANCE SHEET DATA
Current assets Rs m7,6395,102 149.7%   
Current liabilities Rs m2,7152,385 113.8%   
Net working cap to sales %28.545.6 62.6%  
Current ratio x2.82.1 131.6%  
Inventory Days Days43150 28.8%  
Debtors Days Days79113 69.4%  
Net fixed assets Rs m6,9145,148 134.3%   
Share capital Rs m177158 111.8%   
"Free" reserves Rs m11,4426,556 174.5%   
Net worth Rs m11,7216,732 174.1%   
Long term debt Rs m149952 15.6%   
Total assets Rs m14,81410,388 142.6%  
Interest coverage x112.9-45.8 -246.7%   
Debt to equity ratio x00.1 9.0%  
Sales to assets ratio x1.20.6 203.1%   
Return on assets %27.47.5 365.3%  
Return on equity %34.212.0 286.1%  
Return on capital %46.514.6 318.6%  
Exports to sales %55.174.5 74.1%   
Imports to sales %6.024.8 24.2%   
Exports (fob) Rs m9,5274,441 214.5%   
Imports (cif) Rs m1,0381,477 70.2%   
Fx inflow Rs m10,4225,298 196.7%   
Fx outflow Rs m1,6781,772 94.7%   
Net fx Rs m8,7443,525 248.0%   
CASH FLOW
From Operations Rs m3,2641,274 256.2%  
From Investments Rs m-2,093-1,204 173.8%  
From Financial Activity Rs m-1,186-196 604.6%  
Net Cashflow Rs m-15-126 11.7%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 1.6 0.3 516.7%  
FIIs % 7.6 9.6 79.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 9.1 186.8%  
Shareholders   20,968 42,599 49.2%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Down; Tata Steel Top Loser(09:30 am)

Asian stocks rose in morning trade on Monday, after the US's S&P 500 extended its winning streak on Friday to six days. Markets in the Greater China region remain closed for the Lunar New Year holiday.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 19, 2018 10:27 AM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS